Hiregoudar Vandana, Bellara Raghavendra, Goud T Gangadhar
Department of Community Medicine, SDMCMS&H, Sattur, Dharwad, Karnataka, India.
Int J Prev Med. 2019 Dec 10;10:206. doi: 10.4103/ijpvm.IJPVM_7_18. eCollection 2019.
Antiretroviral therapy (ART) significantly delays the progression from HIV to AIDS. Adherence to ART is the second strongest predictor of progression to AIDS and death, after CD4 count. A very high level of adherence (≥95%) is required for ART to be effective on a long term and to prevent the emergence of resistant viral strains and prevent comorbidities.
A case series study was undertaken at an ART center for a period of 6 months. Non-probability purposive sampling was adapted to select HIV-positive subjects aged >15 years on ART for more than 6 months. A predesigned semi-structured questionnaire was used to obtain the data. Treatment compliance was assessed by self-reported 1-week recall method.
A total of 536 HIV-positive people were interviewed, among which 315 (58.8%) of them were males and 214 (39.9%) were females. Nearly two third of the participants (359, 67.0%) reported ≥95% adherence to treatment. Personal commitments (51, 28.8%) and working time inconvenience (42, 23.7%) were the common reasons for less adherence. On bivariate analysis, married people (OR: 1.586, CI: 1.097-2.292), participants residing in rural area (OR: 1.628, CI: 1.130-2.345), participants not having side effects of drugs (OR: 5.324, CI: 3.491-8.181), participants equipped with better knowledge about ART (OR: 2.019, CI: 1.377-2.961), and participants having support of friends and family members (OR: 1.612, CI: 1.019-2.540) showed a higher level of adherence to ART.
Demographic factors such as marital status, residing in rural area, and other personal factors like having good knowledge about ART, without side effects to drugs, and having support of friends and family members were found to show a high level of adherence to ART.
抗逆转录病毒疗法(ART)显著延缓了从人类免疫缺陷病毒(HIV)感染发展到获得性免疫缺陷综合征(AIDS)的进程。坚持ART治疗是继CD4细胞计数之后,预测发展为AIDS和死亡的第二大重要因素。为使ART长期有效,并预防耐药病毒株的出现及并发症,需要非常高的治疗依从性(≥95%)。
在一个ART中心进行了为期6个月的病例系列研究。采用非概率目的抽样法,选取年龄大于15岁、接受ART治疗超过6个月的HIV阳性患者。使用预先设计的半结构化问卷收集数据。通过自我报告的1周回顾法评估治疗依从性。
共访谈了536名HIV阳性患者,其中男性315名(58.8%),女性214名(39.9%)。近三分之二的参与者(359名,67.0%)报告治疗依从性≥95%。个人承诺(51名,28.8%)和工作时间不便(42名,23.7%)是依从性较低的常见原因。在双变量分析中,已婚者(比值比:1.586,可信区间:1.097 - 2.292)、居住在农村地区的参与者(比值比:1.628,可信区间:1.130 - 2.345)、没有药物副作用的参与者(比值比:5.324,可信区间:3.491 - 8.181)、对抗逆转录病毒疗法有更多了解的参与者(比值比:2.019,可信区间:1.377 - 2.961)以及有朋友和家人支持的参与者(比值比:1.612,可信区间:1.019 - 2.540)对ART的依从性更高。
研究发现,婚姻状况、居住在农村地区等人口统计学因素,以及对抗逆转录病毒疗法了解较多、没有药物副作用、有朋友和家人支持等其他个人因素,与较高的ART治疗依从性相关。